XPOVIO (selinexor) — Topline data
H2 2026
Announce topline data from the event-driven Phase 3 XPORT-MM-031 (EMN29) trial expected in the second half of 2026.Source filing
KPTI biotech catalysts & pipeline
KARYOPHARM THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
XPOVIO (selinexor) — Topline data
H2 2026
We expect to report topline data from all patients in the 60 mg cohort with at least 24 weeks of follow-up in the second half of 2026.Source filing
XPOVIO (selinexor) — NDA/BLA submission
Mar 15
The Company will undertake to obtain the Consent by a date no later than March 15, 2027 (the "Consent Deadline").Source filing